Trastuzumab is a monoclonal antibody against HER2-positive breast cancer. Despite improving the natural history of the disease, there is a number of patients who are resistant to it, whereas all patients will eventually develop resistance and disease will progress. Inconsistent preclinical data show that the IGF-R pathway may contribute to either de novo or acquired resistance to trastuzumab.

中文翻译：

---

曲妥珠单抗治疗晚期乳腺癌患者的胰岛素样生长因子受体途径的评估。

曲妥珠单抗是针对HER2阳性乳腺癌的单克隆抗体。尽管改善了疾病的自然病程，但仍有许多患者对此有抗药性，而所有患者最终都将产生抗药性，疾病将会发展。不一致的临床前数据表明，IGF-R途径可能有助于从头产生或获得对曲妥珠单抗的耐药性。